I. Dedov, G. Melnichenko, L. Dzeranova, E. Andreeva, E. Grineva, E. Marova, N. Mokrysheva, E. Pigarova, S. Vorotnikova, N. Fedorova, A. Shutova, E. Przhiyalkovskaya, I.A. Ilovaуskaya, T. Romantsova, S. Dogadin, L. A. Suplotova
Hyperprolactinemia is a persistent excess of the blood serum prolactin. The syndrome contains various symptoms, the most characteristic is a violation of the reproductive system. There are multiple endogenous and exogenous causes of hyperprolactinemia. The main treatment method is dopamine agonist therapy, in case of prolactinoma existence, surgical and radiation methods can be applied. About 15% of patients are resistant to dopamine agonist therapy, which determines creation of individual management tactics. The article presents a draft of clinical guidelines for the diagnosis and treatment of hyperprolactinemia, which provides a modern examination algorithm, discusses the basic principles of diagnostics and treatment approaches.
{"title":"Clinical guidelines ‘Hyperprolactinemia’ (draft)","authors":"I. Dedov, G. Melnichenko, L. Dzeranova, E. Andreeva, E. Grineva, E. Marova, N. Mokrysheva, E. Pigarova, S. Vorotnikova, N. Fedorova, A. Shutova, E. Przhiyalkovskaya, I.A. Ilovaуskaya, T. Romantsova, S. Dogadin, L. A. Suplotova","doi":"10.14341/omet13002","DOIUrl":"https://doi.org/10.14341/omet13002","url":null,"abstract":"Hyperprolactinemia is a persistent excess of the blood serum prolactin. The syndrome contains various symptoms, the most characteristic is a violation of the reproductive system. There are multiple endogenous and exogenous causes of hyperprolactinemia. The main treatment method is dopamine agonist therapy, in case of prolactinoma existence, surgical and radiation methods can be applied. About 15% of patients are resistant to dopamine agonist therapy, which determines creation of individual management tactics. The article presents a draft of clinical guidelines for the diagnosis and treatment of hyperprolactinemia, which provides a modern examination algorithm, discusses the basic principles of diagnostics and treatment approaches.","PeriodicalId":54700,"journal":{"name":"Obesity and Metabolism-Milan","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45843176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nour El Yakine Lakhdar, D. Lamri, Moulay laarbi Ouahidi
BACKGROUND: Obesity, expressed as a high body mass index (BMI), is associated with a risk of decrease in functional capacity and muscle strength, in particular in weight-bearing joints, but so far, no study has been able to show a sufficiently strong relationship between these factors. two options in conclusion.AIM: This study was conducted to quantify the effect of intense exercise on the functional capacity and muscle power of obese individuals and the risk of knee osteoarthritis.MATERIALS AND METHODS: The present research project is characterized as a clinical trial, cross-sectional, and uncontrolled research. All participants had a body mass index from 30.6 kg/m² to 34.9 kg/m² and reported not working out in the last 3 months prior to this experiment. Before their involvement, all participants were informed during an initial interview about the experimental procedure, the nature of the research, and the test protocols. They gave their written and signed informed consent to voluntarily participate in this research and completed two questionnaires. Participants in our study were recruited from sports centers, social clubs, and word of mouth. A total of 78 participants responded to the call articipated in our training protocol which was composed of two main parts. The first one is the «Anthropometric measurements tests» and the second one is the «Functional capacity tests» that were done in a gym. The participants were divided randomly into two experimental. After the end of every phase of the experiment, some members of each group were moved randomly to the other group.RESULTS: The final results of the intra-class correlation coefficient measurements for a set of tests showed strong reliability among members of each examined group. For the handgrip strength tests of the right and left hands, the results were 0.850 and 0.892, respectively. For the squat jump and countermovement jump tests, the results were 0.966 and 0.932, respectively. The results were 0.896 and 0.945 for walking 6 meters with or without double tasks. Finally, for the TUG and TUP-DT tests, the results were 0.520 and 0.663, respectively. After analyzing and interpreting the data for the functional capacity tests, the following results were obtained: For the 5 sit-stand test, the result was (F (3.87)=4.22; p=0.008, ηp2=0.127). For the Time up and go test, the result was (F (3.87)=4.56; p=0.019, ηp2=0.136), and for the 6 m walk, the result was (F (3.87)=3.81; p=0.013, ηp2=0.116). Finally, the 5X sit-to-stand test at 48 hours was lower than the base value (p=0.024), while the TUG immediately after the post was lower than the base value.CONCLUSION: In conclusion, the results of this study demonstrate the positive impact of intense exercise on muscle power and functional capacity in obese individuals. These findings suggest that high-intensity physical activity may be an effective means of improving the health and quality of life of obese individuals. Therefore, it is recommended tha
{"title":"The effect of intense exercise on muscle power and functional abilities of obese people","authors":"Nour El Yakine Lakhdar, D. Lamri, Moulay laarbi Ouahidi","doi":"10.14341/omet12811","DOIUrl":"https://doi.org/10.14341/omet12811","url":null,"abstract":"BACKGROUND: Obesity, expressed as a high body mass index (BMI), is associated with a risk of decrease in functional capacity and muscle strength, in particular in weight-bearing joints, but so far, no study has been able to show a sufficiently strong relationship between these factors. two options in conclusion.AIM: This study was conducted to quantify the effect of intense exercise on the functional capacity and muscle power of obese individuals and the risk of knee osteoarthritis.MATERIALS AND METHODS: The present research project is characterized as a clinical trial, cross-sectional, and uncontrolled research. All participants had a body mass index from 30.6 kg/m² to 34.9 kg/m² and reported not working out in the last 3 months prior to this experiment. Before their involvement, all participants were informed during an initial interview about the experimental procedure, the nature of the research, and the test protocols. They gave their written and signed informed consent to voluntarily participate in this research and completed two questionnaires. Participants in our study were recruited from sports centers, social clubs, and word of mouth. A total of 78 participants responded to the call articipated in our training protocol which was composed of two main parts. The first one is the «Anthropometric measurements tests» and the second one is the «Functional capacity tests» that were done in a gym. The participants were divided randomly into two experimental. After the end of every phase of the experiment, some members of each group were moved randomly to the other group.RESULTS: The final results of the intra-class correlation coefficient measurements for a set of tests showed strong reliability among members of each examined group. For the handgrip strength tests of the right and left hands, the results were 0.850 and 0.892, respectively. For the squat jump and countermovement jump tests, the results were 0.966 and 0.932, respectively. The results were 0.896 and 0.945 for walking 6 meters with or without double tasks. Finally, for the TUG and TUP-DT tests, the results were 0.520 and 0.663, respectively. After analyzing and interpreting the data for the functional capacity tests, the following results were obtained: For the 5 sit-stand test, the result was (F (3.87)=4.22; p=0.008, ηp2=0.127). For the Time up and go test, the result was (F (3.87)=4.56; p=0.019, ηp2=0.136), and for the 6 m walk, the result was (F (3.87)=3.81; p=0.013, ηp2=0.116). Finally, the 5X sit-to-stand test at 48 hours was lower than the base value (p=0.024), while the TUG immediately after the post was lower than the base value.CONCLUSION: In conclusion, the results of this study demonstrate the positive impact of intense exercise on muscle power and functional capacity in obese individuals. These findings suggest that high-intensity physical activity may be an effective means of improving the health and quality of life of obese individuals. Therefore, it is recommended tha","PeriodicalId":54700,"journal":{"name":"Obesity and Metabolism-Milan","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49324144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Mikhaylova, B. Pinkhasov, M. Sorokin, V. Selyatitskaya
BACKGROUND: Actual nutrition and eating behavior features affect the formation of excess or underweight which in turn are risk factors for the development of chronic non-infectious diseases.AIM: To assess eating behavior features and consumption of basic nutrients in relation to metabolic disorders in underweight and obese young men of military age.MATERIALS AND METHODS: The study enrolled 86 young men aged 18 to 23 years that were referred by military enlistment office due to violations in body weight and examined in the hospital. Participants were divided into 2 groups depending on the value of the body mass index (BMI): group 1 (n=41) — underweight (Uw) young men; group 2 (n=45) — obese (Ob) young men. Anthropometric, hormonal and biochemical parameters of the body were measured; the type of eating disorder (ED) was evaluated using the Dutch DEBQ questionnaire, the presence and severity of anxiety and depressive disorders were assessed using the Hospital Anxiety and Depression Scale; assessment of the actual diet was performed using «Somatonic» computer soft.RESULTS: Absolute intake of all essential nutrients was higher in Ob young men; the relative consumption of protein and cholesterol was higher in Uw young men, whereas relative fats intake was higher in Ob group. EDs were statistically significantly more common in Ob young men. The values of all anthropometric indicators were higher in Ob group, while Uw young men predominantly demonstrated deficiency of the body fat component which did not affect key hormonal and metabolic indicators values. In Ob young men carbohydrate metabolism hormonal regulation disorders along with increased blood pressure were revealed.CONCLUSION: The ratio of proteins and fats intake should be taken into account in dietary regimens composition; Uw young men need to increase the proportion of fat and reduce protein intake, whereas Ob young men on the contrary need to reduce the proportion of fat and increase amount of proteins enhancing energy expenditure due to the specific dynamic food action.
{"title":"Eating behavior features and preferred diets in underweight and obese young men","authors":"N. Mikhaylova, B. Pinkhasov, M. Sorokin, V. Selyatitskaya","doi":"10.14341/omet12955","DOIUrl":"https://doi.org/10.14341/omet12955","url":null,"abstract":"BACKGROUND: Actual nutrition and eating behavior features affect the formation of excess or underweight which in turn are risk factors for the development of chronic non-infectious diseases.AIM: To assess eating behavior features and consumption of basic nutrients in relation to metabolic disorders in underweight and obese young men of military age.MATERIALS AND METHODS: The study enrolled 86 young men aged 18 to 23 years that were referred by military enlistment office due to violations in body weight and examined in the hospital. Participants were divided into 2 groups depending on the value of the body mass index (BMI): group 1 (n=41) — underweight (Uw) young men; group 2 (n=45) — obese (Ob) young men. Anthropometric, hormonal and biochemical parameters of the body were measured; the type of eating disorder (ED) was evaluated using the Dutch DEBQ questionnaire, the presence and severity of anxiety and depressive disorders were assessed using the Hospital Anxiety and Depression Scale; assessment of the actual diet was performed using «Somatonic» computer soft.RESULTS: Absolute intake of all essential nutrients was higher in Ob young men; the relative consumption of protein and cholesterol was higher in Uw young men, whereas relative fats intake was higher in Ob group. EDs were statistically significantly more common in Ob young men. The values of all anthropometric indicators were higher in Ob group, while Uw young men predominantly demonstrated deficiency of the body fat component which did not affect key hormonal and metabolic indicators values. In Ob young men carbohydrate metabolism hormonal regulation disorders along with increased blood pressure were revealed.CONCLUSION: The ratio of proteins and fats intake should be taken into account in dietary regimens composition; Uw young men need to increase the proportion of fat and reduce protein intake, whereas Ob young men on the contrary need to reduce the proportion of fat and increase amount of proteins enhancing energy expenditure due to the specific dynamic food action.","PeriodicalId":54700,"journal":{"name":"Obesity and Metabolism-Milan","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42354379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. R. Shodiev, V. Zvyagina, M. N. Ryabova, M. Dmitrieva
BACKGROUND: Currently, OA is considered a polyetiological disease, where several phenotypes are distinguished based on the leading role of a specific risk factor. It is assumed that each clinical phenotype corresponds to its own fundamental changes in various organs and systems. Modern experimental evidence of chondro-osteogenic activity allows us to consider melatonin as a potential drug for various types of osteoarticular pathology.AIM: To study clinical and biochemical changes and effects of melatonin in the metabolic phenotype of OA and insomnia.MATERIALS AND METHODS: The study involved patients with a metabolic phenotype of OA and healthy volunteers. The subjects were collected complaints and anamnesis, as well as general clinical and orthopedic examination. In the blood serum, markers of bone and cartilage metabolism were determined. Patients were asked to answer the questions of clinical scales to assess the quality of sleep, the functional state of the joints and quality of life.RESULTS: The study involved 36 patients. Participants were divided into 3 groups: group health patients — patients without articular pathology, sleep quality disorders and normal body mass index; control group- patients with metabolic phenotype of OA, insomnia and basic treatment for 30 days; experimental group — patients with a metabolic phenotype of OA and insomnia, whose basic treatment included melatonin (Melaxen®) at a dosage of 3 mg for 30 days. Statistically significant differences were observed between the initial levels of acid phosphatase (AP), bone isoenzyme alkaline phosphatase (ALP) and calcium (Ca) in the control and experimental groups. According to the results of screening for the detection of insomnia among patients with the metabolic phenotype of, there were statistically significant insomnological disorders compared to the group health patients, as well as significant differences in terms of pain, symptoms, activity and quality of life in general according to the KOOS and SF-36 scales. Correlation analysis showed moderate correlations with biochemical parameters in patients with OA metabolic phenotype groups. After the treatment there was a certain increase in the level of Ca and a decrease in the activity of ALP and АP in patients of experimental group in comparison with patients of control groups. There was a positive trend in the range of criteria of the KOOS and SF-36 scale in experimental groups, pronounced decrease in pain syndrome (P), symptoms (S) and an increase in the levels of daily activity (A) and the total indicator (Sum) in comparison with patients of control groups. Also as improved sleep quality on all scales in comparison with the control group. In control group, problems with the quality and quantity of sleep remained at the same level.CONCLUSION: In patients with the most pronounced indicators of clinical manifestations of OA, more active processes of bone remodeling. The higher the level of bone resorption markers, the great
{"title":"Clinical and biochemical changes and their correction in patients with metabolic phenotype of osteoarthritis and insomnia","authors":"D. R. Shodiev, V. Zvyagina, M. N. Ryabova, M. Dmitrieva","doi":"10.14341/omet12888","DOIUrl":"https://doi.org/10.14341/omet12888","url":null,"abstract":"BACKGROUND: Currently, OA is considered a polyetiological disease, where several phenotypes are distinguished based on the leading role of a specific risk factor. It is assumed that each clinical phenotype corresponds to its own fundamental changes in various organs and systems. Modern experimental evidence of chondro-osteogenic activity allows us to consider melatonin as a potential drug for various types of osteoarticular pathology.AIM: To study clinical and biochemical changes and effects of melatonin in the metabolic phenotype of OA and insomnia.MATERIALS AND METHODS: The study involved patients with a metabolic phenotype of OA and healthy volunteers. The subjects were collected complaints and anamnesis, as well as general clinical and orthopedic examination. In the blood serum, markers of bone and cartilage metabolism were determined. Patients were asked to answer the questions of clinical scales to assess the quality of sleep, the functional state of the joints and quality of life.RESULTS: The study involved 36 patients. Participants were divided into 3 groups: group health patients — patients without articular pathology, sleep quality disorders and normal body mass index; control group- patients with metabolic phenotype of OA, insomnia and basic treatment for 30 days; experimental group — patients with a metabolic phenotype of OA and insomnia, whose basic treatment included melatonin (Melaxen®) at a dosage of 3 mg for 30 days. Statistically significant differences were observed between the initial levels of acid phosphatase (AP), bone isoenzyme alkaline phosphatase (ALP) and calcium (Ca) in the control and experimental groups. According to the results of screening for the detection of insomnia among patients with the metabolic phenotype of, there were statistically significant insomnological disorders compared to the group health patients, as well as significant differences in terms of pain, symptoms, activity and quality of life in general according to the KOOS and SF-36 scales. Correlation analysis showed moderate correlations with biochemical parameters in patients with OA metabolic phenotype groups. After the treatment there was a certain increase in the level of Ca and a decrease in the activity of ALP and АP in patients of experimental group in comparison with patients of control groups. There was a positive trend in the range of criteria of the KOOS and SF-36 scale in experimental groups, pronounced decrease in pain syndrome (P), symptoms (S) and an increase in the levels of daily activity (A) and the total indicator (Sum) in comparison with patients of control groups. Also as improved sleep quality on all scales in comparison with the control group. In control group, problems with the quality and quantity of sleep remained at the same level.CONCLUSION: In patients with the most pronounced indicators of clinical manifestations of OA, more active processes of bone remodeling. The higher the level of bone resorption markers, the great","PeriodicalId":54700,"journal":{"name":"Obesity and Metabolism-Milan","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44107455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. A. Suplotova, O. O. Alieva, T. S. Dushina, O. Makarova
Today there is a worldwide trend of population aging, in addition, the proportion of older people with obesity is increasing. In order to adequately manage these patients in the outpatient setting, it is critical to understand the dynamic relationship between body weight, chronic disease prevalence, development of functional disability, life expectancy, and health care costs. While the obesity epidemic has affected people of all age groups, empirical knowledge about the management of obese older people remains largely scarce. Currently, there is no single therapeutic approach to this problem. Weight loss should be treated with caution in people over 60 years of age. The risk of sarcopenia, malnutrition, bone loss, increased risk of falls and injury must be considered, which can lead to an increase in the number of people with disabilities and the associated costs of medical and social care. The analytical review focuses on the relationship between two of the greatest epidemiological trends: aging and obesity. This paper highlights the features of the pathophysiology of obesity in the elderly, the phenomenon of the «obesity paradox». Also from the perspective of evidence-based medicine approaches to the treatment of obesity in the elderly, including surgical interventions aimed at reducing body weight, are analyzed.
{"title":"Obesity in the elderly: peculiarities of treatment in outpatient practice","authors":"L. A. Suplotova, O. O. Alieva, T. S. Dushina, O. Makarova","doi":"10.14341/omet12919","DOIUrl":"https://doi.org/10.14341/omet12919","url":null,"abstract":"Today there is a worldwide trend of population aging, in addition, the proportion of older people with obesity is increasing. In order to adequately manage these patients in the outpatient setting, it is critical to understand the dynamic relationship between body weight, chronic disease prevalence, development of functional disability, life expectancy, and health care costs. While the obesity epidemic has affected people of all age groups, empirical knowledge about the management of obese older people remains largely scarce. Currently, there is no single therapeutic approach to this problem. Weight loss should be treated with caution in people over 60 years of age. The risk of sarcopenia, malnutrition, bone loss, increased risk of falls and injury must be considered, which can lead to an increase in the number of people with disabilities and the associated costs of medical and social care. The analytical review focuses on the relationship between two of the greatest epidemiological trends: aging and obesity. This paper highlights the features of the pathophysiology of obesity in the elderly, the phenomenon of the «obesity paradox». Also from the perspective of evidence-based medicine approaches to the treatment of obesity in the elderly, including surgical interventions aimed at reducing body weight, are analyzed.","PeriodicalId":54700,"journal":{"name":"Obesity and Metabolism-Milan","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45659552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Alieva, A. Djalilov, F. A. Khaydarova, A. V. Alimov, D. Khalilova, V. Talenova, N. Alimova, M. D. Aripova, A. Sadikova
BACKGROUND: Since the very first outbreak, scientists have been trying to determine the most critical pathogenetic mechanisms for the development of COVID-19 and related complications, analyze individual subpopulations of patients with chronic diseases and develop optimal tactics to combat not only the infection itself but also its acute and chronic complications.AIM: to assess the COVID-19 course among patients with Type 1 and Type 2 DM.MATERIALS AND METHODS: A retrospective cohort study of Tashkent inhabitants, who had COVID-19 from April to D ecember 2020, was performed. The data were obtained from the single electronic database of registered cases of COVID-19. All data were analyzed using a logistic regression in STATA 17.0 software. Further, the matched case-control study was performed for patients with type 2 DM and no DM based on age, gender, and BMI.RESULTS: Of the 5023 analyzed subjects, 72.63% had no diabetes mellitus (DM), 4.24% had type 1 DM, 15.19% had type 2 DM, and 7.94% was diagnosed with DM during the COVID-19 infection. DM, overweight, and obesity were associated with severe COVID-19; the most significant risk of a severe course was found in persons with type 2 DM. The risk of a lethal outcome and the need for prescription of glucocorticoids did not show a significant association with diabetes in Tashkent. The clinical features of COVID-19 were more common in patients with type 2 DM, especially for shortness of breath, chest pain, and arrhythmia. The persons receiving SU have complained of dyspnea significantly more often than matched patients without DM. Metformin and DPP4i were the groups of drugs that were not associated with significantly increased risk of hospitalization of patients because of COVID-19. The matched case-control study did not reveal statistically significant differences in the disease course severity, need for hospitalization and glucocorticoids, and death depending on the glucose-lowering therapy preceding the onset of COVID-19.CONCLUSION: Diabetes, age and overweight/obesity were associated with severe course of COVID-19 in Tashkent. There was no statistical difference in COVID-19 severity depending on initial glucose-lowering therapy.
{"title":"Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study","authors":"A. Alieva, A. Djalilov, F. A. Khaydarova, A. V. Alimov, D. Khalilova, V. Talenova, N. Alimova, M. D. Aripova, A. Sadikova","doi":"10.14341/omet12801","DOIUrl":"https://doi.org/10.14341/omet12801","url":null,"abstract":"BACKGROUND: Since the very first outbreak, scientists have been trying to determine the most critical pathogenetic mechanisms for the development of COVID-19 and related complications, analyze individual subpopulations of patients with chronic diseases and develop optimal tactics to combat not only the infection itself but also its acute and chronic complications.AIM: to assess the COVID-19 course among patients with Type 1 and Type 2 DM.MATERIALS AND METHODS: A retrospective cohort study of Tashkent inhabitants, who had COVID-19 from April to D ecember 2020, was performed. The data were obtained from the single electronic database of registered cases of COVID-19. All data were analyzed using a logistic regression in STATA 17.0 software. Further, the matched case-control study was performed for patients with type 2 DM and no DM based on age, gender, and BMI.RESULTS: Of the 5023 analyzed subjects, 72.63% had no diabetes mellitus (DM), 4.24% had type 1 DM, 15.19% had type 2 DM, and 7.94% was diagnosed with DM during the COVID-19 infection. DM, overweight, and obesity were associated with severe COVID-19; the most significant risk of a severe course was found in persons with type 2 DM. The risk of a lethal outcome and the need for prescription of glucocorticoids did not show a significant association with diabetes in Tashkent. The clinical features of COVID-19 were more common in patients with type 2 DM, especially for shortness of breath, chest pain, and arrhythmia. The persons receiving SU have complained of dyspnea significantly more often than matched patients without DM. Metformin and DPP4i were the groups of drugs that were not associated with significantly increased risk of hospitalization of patients because of COVID-19. The matched case-control study did not reveal statistically significant differences in the disease course severity, need for hospitalization and glucocorticoids, and death depending on the glucose-lowering therapy preceding the onset of COVID-19.CONCLUSION: Diabetes, age and overweight/obesity were associated with severe course of COVID-19 in Tashkent. There was no statistical difference in COVID-19 severity depending on initial glucose-lowering therapy.","PeriodicalId":54700,"journal":{"name":"Obesity and Metabolism-Milan","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42882779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. K. Ilyushchenko, L. Machekhina, I. Strazhesko, O. Tkacheva
One of the most important trends in geroscience is the search for the biomechanisms of aging and geroprotective methods. In recent years, more and more attention has been paid to the role of age-related decline in IGF-1 levels; processes that start with a decrease in the activity of the GH/IGF-1 axis. IGF-1 levels correlate differently with many age-associated diseases: diabetes mellitus, cancer, cardiovascular disease. A decrease in the level of IGF-1 and growth hormone in the elderly can contribute to the deterioration of the course of some pathologies, and also have a protective effect in the occurrence of different nosologies. The possibility of slowing down aging with the help of IGF-1 in basic research led to research aimed at studying the possibility of using IGF-1 preparations and growth hormone in clinical practice to slow down aging. We have studied the literature on the Pubmed platform, Scopus for the past 10 years in order to find some new information regarding influence of IGF-1 on aging, about the association between IGF-1 levels and major age-related diseases. We analyzed data of publications on the role of IGF-1 in aging and the development of age-related diseases. The search was carried out using key words: IGF-1, growth hormone, aging, the review included data from more than 60 publications.
{"title":"The role of IGF-1/GH in the aging process and the development of age-related diseases","authors":"A. K. Ilyushchenko, L. Machekhina, I. Strazhesko, O. Tkacheva","doi":"10.14341/omet12934","DOIUrl":"https://doi.org/10.14341/omet12934","url":null,"abstract":"One of the most important trends in geroscience is the search for the biomechanisms of aging and geroprotective methods. In recent years, more and more attention has been paid to the role of age-related decline in IGF-1 levels; processes that start with a decrease in the activity of the GH/IGF-1 axis. IGF-1 levels correlate differently with many age-associated diseases: diabetes mellitus, cancer, cardiovascular disease. A decrease in the level of IGF-1 and growth hormone in the elderly can contribute to the deterioration of the course of some pathologies, and also have a protective effect in the occurrence of different nosologies. The possibility of slowing down aging with the help of IGF-1 in basic research led to research aimed at studying the possibility of using IGF-1 preparations and growth hormone in clinical practice to slow down aging. We have studied the literature on the Pubmed platform, Scopus for the past 10 years in order to find some new information regarding influence of IGF-1 on aging, about the association between IGF-1 levels and major age-related diseases. We analyzed data of publications on the role of IGF-1 in aging and the development of age-related diseases. The search was carried out using key words: IGF-1, growth hormone, aging, the review included data from more than 60 publications.","PeriodicalId":54700,"journal":{"name":"Obesity and Metabolism-Milan","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48945960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUND: Liraglutide was approved for treatment of obesity in children and adolescents since 12 years. Due to gastrointestinal (GI) side effects not all patients reach maximal dose; this can affect the efficacy of obesity treatment.AIM: To study efficacy and tolerability of liraglutide in adolescents with obesity.MATERIALS AND METHODS: We analyzed medical data of adolescents with simple obesity and GI comorbidities before and in 3 months after start of liraglutide (BMI SDS; obesity complications; liraglutide side effects, and maximal doses), duration of therapy, reasons for discontinuation, and BMI SDS in 3–6 months after discontinuation.RESULTS: Liraglutide was administered for 10 adolescents (7 girls, 3 boys) 15.4 (13.5; 16.2) years with BMI SDS 3.3 (2.9; 3.7). Three months of treatment led to significant (p=0.001) decrease of BMI SDS till 2.8 (2.6; 3.5). Maximal dose of liraglutide was 3.0 mg (6 patients), 2.4 mg (2), 1.8 mg (1), and 1.2 mg (1). No correlation between maximal dose and BMI ΔSDS was detected. While dose titration patients complained of nausea (9), diarrhea (3), obstipation (1), and flatulence (1). In majority of cases complains were not dose-dependent. Only in 1 patient nausea and diarrhea that did not allow to increase liraglutide dose above 1.2 mg; additional investigation after discontinuation of therapy revealed GI infection.Therapy was discontinued in 3 months by 2 patients (1 — side effects, 1 — satisfactory result), in 4–5 months by 3 patients (1 — relapse of excessive weight gain, 2 — financial reasons), in 6 months by 1 patient (satisfactory result); 4 continued therapies. In 3–6 months after discontinuation of therapy BMI SDS increased and did not significantly differ from basal.CONCLUSION: Liraglutide is effective for treatment of obesity in adolescents and well tolerated by majority of patients. In case of pronounced adverse events additional GI investigation is recommended. Patients can discontinue treatment not only due to side effects, but also when they achieve their goal, and due to financial reasons.
{"title":"Liraglutide in adolescents with simple obesity and gastrointestinal comorbidities: treatment experience","authors":"A. Vitebskaya, A. V. Popovich","doi":"10.14341/omet12922","DOIUrl":"https://doi.org/10.14341/omet12922","url":null,"abstract":"BACKGROUND: Liraglutide was approved for treatment of obesity in children and adolescents since 12 years. Due to gastrointestinal (GI) side effects not all patients reach maximal dose; this can affect the efficacy of obesity treatment.AIM: To study efficacy and tolerability of liraglutide in adolescents with obesity.MATERIALS AND METHODS: We analyzed medical data of adolescents with simple obesity and GI comorbidities before and in 3 months after start of liraglutide (BMI SDS; obesity complications; liraglutide side effects, and maximal doses), duration of therapy, reasons for discontinuation, and BMI SDS in 3–6 months after discontinuation.RESULTS: Liraglutide was administered for 10 adolescents (7 girls, 3 boys) 15.4 (13.5; 16.2) years with BMI SDS 3.3 (2.9; 3.7). Three months of treatment led to significant (p=0.001) decrease of BMI SDS till 2.8 (2.6; 3.5). Maximal dose of liraglutide was 3.0 mg (6 patients), 2.4 mg (2), 1.8 mg (1), and 1.2 mg (1). No correlation between maximal dose and BMI ΔSDS was detected. While dose titration patients complained of nausea (9), diarrhea (3), obstipation (1), and flatulence (1). In majority of cases complains were not dose-dependent. Only in 1 patient nausea and diarrhea that did not allow to increase liraglutide dose above 1.2 mg; additional investigation after discontinuation of therapy revealed GI infection.Therapy was discontinued in 3 months by 2 patients (1 — side effects, 1 — satisfactory result), in 4–5 months by 3 patients (1 — relapse of excessive weight gain, 2 — financial reasons), in 6 months by 1 patient (satisfactory result); 4 continued therapies. In 3–6 months after discontinuation of therapy BMI SDS increased and did not significantly differ from basal.CONCLUSION: Liraglutide is effective for treatment of obesity in adolescents and well tolerated by majority of patients. In case of pronounced adverse events additional GI investigation is recommended. Patients can discontinue treatment not only due to side effects, but also when they achieve their goal, and due to financial reasons.","PeriodicalId":54700,"journal":{"name":"Obesity and Metabolism-Milan","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43572393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUND: Diabetes mellitus, one of the most common chronic diseases in the world, has a significant aggravating effect on the course of myocardial infarction. Thioctic acid affects the cardiovascular risks of diabetes mellitus and has a protective effect on ischemic myocardium. Human studies to support this effect have not been widely conducted.AIM: To confirm the possibility of using thioctic acid in patients with diabetes mellitus or newly diagnosed diabetes mellitus in combination with diabetic polyneuropathy who have had anterior septal Q wave myocardial infarction to prevent hypertrophy and myocardial remodeling.MATERIALS AND METHODS: The study involved patients with myocardial infarction and type 2 diabetes mellitus, newly diagnosed diabetes mellitus and diabetic polyneuropathy. From the obtained groups, by randomization, subgroups were allocated to which thioctic acid was prescribed at a dosage of 600 mg / day orally for 3 months. To determine the comparability of the groups, a standard set of stationary studies was carried out. At the initial stage and 12 months after the start of the study, the echocardiographic parameters of myocardial hypertrophy and remodeling were monitored.RESULTS: The study involved 125 people, 5 people were excluded due to the development of unwanted adverse reactions. The formed groups were comparable in terms of initial parameters. In the main subgroups, statistically significant dynamics of LV wall hypertrophy and myocardial remodeling were not revealed. In the control subgroup of patients with diabetes mellitus, an increase in the thickness of the IVS was noted by 0.67 mm [95% CI: 0.4–0.94, p = 0.021], LVTZ by 0.8 mm [95% CI: 0.43–1 , 27, p = 0.043], LVMI at 9.2 g / m2 [95% CI: 6.15–12.24, p = 0.05], LVMI at 17.8 g. [95% CI: 11.3–24.3, p = 0.011], an increase in the prevalence of concentric myocardial remodeling by 16.7% (p = 0.026). In the control subgroup of patients with newly diagnosed diabetes mellitus, an increase in the thickness of the IVS was noted by 0.83 mm 95% [CI: 0.43–1.23, p = 0.047], LVMI by 7.9 g / m2 [95% CI: 4 , 47–11.43, p = 0.033], LVM at 16.7 gr. [95% CI: 9.75–23.65, p = 0.023], an increase in the prevalence of concentric myocardial remodeling by 16.7% (p = 0.026). In the main subgroup of patients with diabetes mellitus, a decrease in LVMM by 3.33 g was noted. [95% CI: 1.94–4.72, p = 0.024], LVMI at 4.19 g / m2 [95% CI: 2.18–6.2, p = 0.047].CONCLUSION: The use of thioctic acid on the 3rd day from antero-septal Q wave myocardial infarction in patients with type 2 diabetes, newly diagnosed diabetes mellitus, in combination with diabetic polyneuropathy, at a dosage of 600 mg / day orally, prevents hypertrophy and myocardial remodeling, and also contributes to the positive dynamics of the structure of the ejection fraction.
背景：糖尿病是世界上最常见的慢性疾病之一，对心肌梗死的病程有显著的加重作用。硫辛酸影响糖尿病的心血管风险，并对缺血心肌具有保护作用。支持这种影响的人体研究尚未广泛开展。目的：证实在糖尿病患者或新诊断的糖尿病合并糖尿病多发性神经病合并前间隔Q波心肌梗死的患者中使用硫辛酸预防心肌肥大和心肌重塑的可能性。材料和方法：本研究涉及心肌梗死和2型糖尿病、新诊断的糖尿病和糖尿病多发性神经病患者。从获得的组中，通过随机分组，将亚组分配给口服剂量为600mg/天的硫辛酸，持续3个月。为了确定各组的可比性，进行了一组标准的固定研究。在研究开始的最初阶段和12个月后，监测心肌肥大和重塑的超声心动图参数。结果：该研究涉及125人，其中5人因出现不良反应而被排除在外。所形成的组在初始参数方面具有可比性。在主要亚组中，左心室壁肥大和心肌重塑的动力学没有显示出统计学意义。在糖尿病患者的对照亚组中，IVS厚度增加了0.67 mm[95%CI:0.4-0.94，p=0.021]，LVTZ增加了0.8 mm[95%CI：0.43-1,27，p=0.043]，LVMI增加了9.2 g/m2[95%CI:6.15–12.24，p=0.05]，LVMI增加了17.8 g[95%CI:11.3–24.3，p=0.011]，同心型心肌重构的发生率增加了16.7%（p=0.026）。在新诊断的糖尿病患者的对照亚组中，IVS厚度增加了0.83 mm 95%[CI:0.43-1.23，p=0.047]，LVMI增加了7.9 g/m2[95%CI:47,47-11.43，p=0.033]，LVM为16.7 gr[95%CI:9.75-23.65，p=0.023]，在糖尿病患者的主要亚组中，LVMM降低了3.33g。[95%CI:1.94–4.72，p=0.024]，LVMI为4.19 g/m2[95%CI:2.18–6.2，p=0.047]，并且也有助于喷射部分的结构的正动力学。
{"title":"Influence of thioctic acid in patients with diabetes mellitus or newly diagnosed diabetes mellitus in combination with diabetic polyneuropathy after anterior septal Q wave myocardial infarction on the prevention of hypertrophy and structural myocardial remodeling","authors":"K. G. Yanovky, L. A. Ivanova","doi":"10.14341/omet12821","DOIUrl":"https://doi.org/10.14341/omet12821","url":null,"abstract":"BACKGROUND: Diabetes mellitus, one of the most common chronic diseases in the world, has a significant aggravating effect on the course of myocardial infarction. Thioctic acid affects the cardiovascular risks of diabetes mellitus and has a protective effect on ischemic myocardium. Human studies to support this effect have not been widely conducted.AIM: To confirm the possibility of using thioctic acid in patients with diabetes mellitus or newly diagnosed diabetes mellitus in combination with diabetic polyneuropathy who have had anterior septal Q wave myocardial infarction to prevent hypertrophy and myocardial remodeling.MATERIALS AND METHODS: The study involved patients with myocardial infarction and type 2 diabetes mellitus, newly diagnosed diabetes mellitus and diabetic polyneuropathy. From the obtained groups, by randomization, subgroups were allocated to which thioctic acid was prescribed at a dosage of 600 mg / day orally for 3 months. To determine the comparability of the groups, a standard set of stationary studies was carried out. At the initial stage and 12 months after the start of the study, the echocardiographic parameters of myocardial hypertrophy and remodeling were monitored.RESULTS: The study involved 125 people, 5 people were excluded due to the development of unwanted adverse reactions. The formed groups were comparable in terms of initial parameters. In the main subgroups, statistically significant dynamics of LV wall hypertrophy and myocardial remodeling were not revealed. In the control subgroup of patients with diabetes mellitus, an increase in the thickness of the IVS was noted by 0.67 mm [95% CI: 0.4–0.94, p = 0.021], LVTZ by 0.8 mm [95% CI: 0.43–1 , 27, p = 0.043], LVMI at 9.2 g / m2 [95% CI: 6.15–12.24, p = 0.05], LVMI at 17.8 g. [95% CI: 11.3–24.3, p = 0.011], an increase in the prevalence of concentric myocardial remodeling by 16.7% (p = 0.026). In the control subgroup of patients with newly diagnosed diabetes mellitus, an increase in the thickness of the IVS was noted by 0.83 mm 95% [CI: 0.43–1.23, p = 0.047], LVMI by 7.9 g / m2 [95% CI: 4 , 47–11.43, p = 0.033], LVM at 16.7 gr. [95% CI: 9.75–23.65, p = 0.023], an increase in the prevalence of concentric myocardial remodeling by 16.7% (p = 0.026). In the main subgroup of patients with diabetes mellitus, a decrease in LVMM by 3.33 g was noted. [95% CI: 1.94–4.72, p = 0.024], LVMI at 4.19 g / m2 [95% CI: 2.18–6.2, p = 0.047].CONCLUSION: The use of thioctic acid on the 3rd day from antero-septal Q wave myocardial infarction in patients with type 2 diabetes, newly diagnosed diabetes mellitus, in combination with diabetic polyneuropathy, at a dosage of 600 mg / day orally, prevents hypertrophy and myocardial remodeling, and also contributes to the positive dynamics of the structure of the ejection fraction.","PeriodicalId":54700,"journal":{"name":"Obesity and Metabolism-Milan","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47205956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The article describes the case of a patient with Wernicke encephalopathy, which developed 3 months after the sleeve gastrectomy. An MRI of the brain was performed to verify the diagnosis, which revealed a symmetrical non-uniform increase in the MR signal on T2-WI and Tirm from the medial part of the thalamus, mastoid bodies and gray matter around the aqueduct of Sylvius. Thiamine infusion was promptly initiated as therapy. During treatment, acute neurological symptoms almost regressed, the patient was discharged in a satisfactory condition with preservation of vertical nystagmus under the supervision of specialists at the place of residence. Wernicke–Korsakoff syndrome more often occurs as a complication of alcoholism and arising from thiamine deficiency. However, the fact that this condition also occurs under the influence of other etiopathogenetic factors is often ignored by clinicians. In the management of patients after bariatric interventions, this condition is much more common in malabsorptive operations. However, a combination of certain factors can be described in patients after restrictive types of bariatric surgeries.
{"title":"Wernicke encephalopathy after sleeve gastrectomy","authors":"A. Neimark, S. Lapshina, M. A. Molotkova","doi":"10.14341/omet12965","DOIUrl":"https://doi.org/10.14341/omet12965","url":null,"abstract":"The article describes the case of a patient with Wernicke encephalopathy, which developed 3 months after the sleeve gastrectomy. An MRI of the brain was performed to verify the diagnosis, which revealed a symmetrical non-uniform increase in the MR signal on T2-WI and Tirm from the medial part of the thalamus, mastoid bodies and gray matter around the aqueduct of Sylvius. Thiamine infusion was promptly initiated as therapy. During treatment, acute neurological symptoms almost regressed, the patient was discharged in a satisfactory condition with preservation of vertical nystagmus under the supervision of specialists at the place of residence. Wernicke–Korsakoff syndrome more often occurs as a complication of alcoholism and arising from thiamine deficiency. However, the fact that this condition also occurs under the influence of other etiopathogenetic factors is often ignored by clinicians. In the management of patients after bariatric interventions, this condition is much more common in malabsorptive operations. However, a combination of certain factors can be described in patients after restrictive types of bariatric surgeries.","PeriodicalId":54700,"journal":{"name":"Obesity and Metabolism-Milan","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45252139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：